Results 61 to 70 of about 11,301 (165)

Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis

BMC Cardiovascular Disorders
Background High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months.
Kaveh Hosseini, Hamidreza Soleimani, Saba Maleki, Amir Nasrollahizadeh, Sima Tayebi, John Nelson, Sean P. Heffron   +6 more
doaj   +1 more source

Impact of specialised endocrinology care on metabolic control and healthcare utilisation outcomes after kidney transplantation in patients with diabetes: A 12‐month observational cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate whether an endocrinology‐integrated transplant clinic and differing healthcare delivery models are associated with metabolic outcomes during the first year after kidney transplantation in recipients with pre‐existing diabetes.
Joaquin Lado‐Abeal, Francisco Gude, Maria Jose Ginzo‐Villamayor, Khalid Al‐Zubaidi, Jacqueline C. Stocking, Gemma Rodriguez‐Carnero, Aili Guo, Prasanth Surampudi, Caroline Lenaerts, Vedesh K. Babu, Deborah Plante, Yihung Huang, Antia Fernandez‐Pombo   +12 more
wiley   +1 more source

High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases

The FEBS Journal, EarlyView.
High serum cholesterol is linked to colorectal cancer liver metastases (CRCLM) subtypes with poor survival (replacement pattern). Levels of cholesterol under 4 mmol·L−1 correlated with better survival and a desmoplastic pattern subtype. Furthermore, in vivo PCSK9 inhibitor evolocumab, which lowers cholesterol, reduced liver metastases.
Amatzia Gantz, Audrey Kapelanski‐Lamoureux, Miran Rada, Lucyna Krzywon, Migmar Tsamchoe, Anastasia Tsatoumas, Stephanie K. Petrillo, Nabil G. Seidah, Anthoula Lazaris, Peter Metrakos   +9 more
wiley   +1 more source

PCSK9 INHIBITORS IN PERIPHERAL ARTERY DISEASE: REVIEW OF EFFICACY, SAFETY, AND OUTCOMES

American Journal of Preventive Cardiology
Therapeutic Area: Peripheral Artery Disease Background: Peripheral artery disease (PAD) is a debilitating condition characterized by atherosclerosis in the peripheral arteries, affecting approximately 200 million people worldwide.
Moiud Mohyeldin
doaj   +1 more source

RNA‐Based Therapies for Inherited Metabolic Disorders

Journal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Inherited metabolic disorders (IMDs) are a diverse and complex group of genetic conditions resulting from deficiencies in enzymes, transporters, or cofactors. These deficiencies lead to metabolic dysfunction and severe clinical consequences. Despite significant progress in understanding their molecular basis, treatment options remain limited ...
Reddy Sreekanth Vootukuri, Sonam Gurung, Roopkatha Ghosh, Philippa B. Mills, Julien Baruteau, Haiyan Zhou   +5 more
wiley   +1 more source

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis

Scientific Reports
Recent case reports linked use of the lipid-lowering class of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to severe hypersensitivity reactions.
Foteini Dermiki-Gkana, Christopher A. Gravel, Christos Kontogiorgis, Antonios Douros   +3 more
doaj   +1 more source

The Evolving Future of PCSK9 Inhibitors

Journal of the American College of Cardiology, 2018
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups.
Robert S, Rosenson, Robert A, Hegele, Sergio, Fazio, Christopher P, Cannon   +3 more
openaire   +2 more sources

Disrupting Lipid Raft Microdomains to Block Polyploid Giant Cancer Cell Budding and Enhance Radiotherapy Response

Advanced Science, Volume 13, Issue 9, 13 February 2026.
Radiation induces polyploid giant cancer cells (PGCCs) that regenerate tumors through virus‐like budding. This process depends on a SNCG–FLOT2–CHMP4B signaling axis functioning in lipid raft microdomains. Disrupting these domains using statins or anti‐PCSK9 antibodies blocks PGCC budding, suppresses tumor repopulation, and enhances radiotherapy ...
Zheng Deng, Haoran Sun, Jin Cheng, Ruyi Zhao, Jianzhu Xie, Yanwei Song, Yucui Zhao, Chenwei Lin, Binjie Hu, Yanping Gong, Jun Lin, Sijia He, Yuntao Luo, Minghui Zhao, Yiwei Wang, Ming Jiao, Yuqin Yang, Jikun Li, Shujie Xia, Chuanyuan Li, Qian Huang   +20 more
wiley   +1 more source

The High Price of Interrupted Follow‐Up: Catastrophic Progression of Homozygous Familial Hypercholesterolemia—A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Familial hypercholesterolemia (FH) is the most common monogenic lipid disorder, primarily resulting from mutations in LDLR, APOB, and PCSK9 genes. These mutations cause persistently high levels of low‐density lipoprotein cholesterol (LDL‐C), predisposing affected individuals to premature atherosclerotic cardiovascular disease (ASCVD ...
Parham Dastjerdi, Mahdieh Aghababaei, Reza Nikfar, Maryam Aghakouchakzadeh, Reza Mohseni‐Badalabadi, Kaveh Hosseini   +5 more
wiley   +1 more source

Preventing Atherosclerotic Cardiovascular Disease in Young Male Androgen Abusers

Clinical Cardiology, Volume 49, Issue 2, February 2026.
Androgen abuse is an underrecognized ASCVD risk enhancer in young men. Improved risk assessment—integrating androgen exposure, imaging, and individualized prevention—may help in the management of long‐term cardiovascular risk in this population. ABSTRACT Background Androgen abuse among young men is a prevalent yet under recognized risk factor for ...
Peter Bond, Diederik L. Smit, Tijs Verdegaal, Willem de Ronde   +3 more
wiley   +1 more source